NCT00956787 - Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

July 31, 2014

Study Completion Date

December 31, 2014

Conditions

Myelodysplastic Syndrome

Interventions

DRUG

AR-67 (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin)

Patients will receive AR-67 at an initial dose of 7.5 mg/m2 IV over 1 hour daily for 5 days. In patients with stable disease, treatment may continue for up to a total of 12 courses of therapy; about 1 to 2 years.

Trial Locations (1)

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston